COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Reports Full Year 2023 Financial Results and Business Update
07/03/2024
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) [...]
DBV Technologies fait le point sur ses activités et publie ses résultats financiers de l’année 2023
07/03/2024
Montrouge, France, 7 mars 2024 DBV Technologies fait le point sur ses activités et publie ses résultats financiers de l’année 2023 Progression des programmes de développement clinique Viaskin™ Peanut chez les jeunes [...]
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/03/2024
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody [...]
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
07/03/2024
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara [...]
The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results
07/03/2024
- Grew 2023 Revenue 16%, System-wide Sales 12%, and System-wide Comp Sales 4% vs. 2022 - - Increased Clinic Count to 935 at Year-end 2023, Initiating Refranchising Program - SCOTTSDALE, Ariz., March 07, 2024 (GLOBE [...]
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
07/03/2024
DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced [...]
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
07/03/2024
Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology [...]
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
07/03/2024
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® ( [...]
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
07/03/2024
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial [...]
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
07/03/2024
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Xtant Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
07/03/2024
BELGRADE, Mont., March 07, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today [...]
RadNet Announces Proposed $200 Million Underwritten Public Offering of Common Stock
07/03/2024
LOS ANGELES, March 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today that it [...]
Industry Veteran Clay Thornton Joins Clover Health as CFO of Medicare Advantage
07/03/2024
Mr. Thornton brings a decade of Medicare Advantage leadership experience FRANKLIN, Tenn., March 07, 2024 (GLOBE NEWSWIRE) -- Today Clover Health ("Clover" or "the Company") announced Clay Thornton as the newly appointed [...]
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
07/03/2024
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to [...]
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
07/03/2024
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced [...]
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
07/03/2024
FOSTER CITY, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
07/03/2024
CARLSBAD, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2023, before the [...]
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
07/03/2024
Significant unmet need with 80-90% of patients with current epinephrine Rx not using as directed, and only ~15% of diagnosed severe Type I allergy population with a current epinephrine prescription Multiple favorable [...]
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supporting its speed to market strategy; topline results from Stage 1 of the study [...]

Pages